Stockscreener 앱 받기
4.675
1.79%
-0.085
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
[ARS] Foghorn Therapeutics Inc. SEC Filing - Stock Titan
Executive pay, major holders and votes in Foghorn (NASDAQ: FHTX) 2026 proxy - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 1.9%Time to Sell? - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating on AACR data - Investing.com
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Should I sell Foghorn Therapeutics (FHTX) stock today | Q4 2025: Earnings UnderperformExpert Momentum Signals - Xã Châu Thành
H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn presents preclinical data for cancer drug candidates By Investing.com - Investing.com South Africa
FHTX Unveils Promising Preclinical Data at AACR Annual Meeting - GuruFocus
Foghorn presents preclinical data for cancer drug candidates - Investing.com
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR - TipRanks
Foghorn Therapeutics presents new preclinical data on SMARCA2 inhibitor FHD-909 and targeted degrader programs - Traders Union
Foghorn Therapeutics Presents New Preclinical Data for - GlobeNewswire
Foghorn Therapeutics (Nasdaq: FHTX) showcases broad preclinical cancer data and cash runway outlook - Stock Titan
Foghorn Therapeutics (FHTX) Stock: Short-Term vs Long-Term (Eye on Rally) 2026-04-15Momentum Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Foghorn (NASDAQ: FHTX) CEO shifts 213,410 shares in trust-to-trust gifts - Stock Titan
If You Invested $1,000 in Foghorn Therapeutics Inc. (FHTX) - Stock Titan
Trading Recap: Can Foghorn Therapeutics Inc weather a recession2026 Spike Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Investing News Network
Foghorn to present preclinical cancer data at AACR meeting By Investing.com - Investing.com South Africa
Foghorn Therapeutics details preclinical advances across oncology programs - Traders Union
Foghorn to present preclinical cancer data at AACR meeting - Investing.com
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor ... - Bluefield Daily Telegraph
Foghorn Therapeutics to Present New Preclinical Data for - GlobeNewswire
FHTX PE Ratio & Valuation, Is FHTX Overvalued - Intellectia AI
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
FHTX Technical Analysis & Stock Price Forecast - Intellectia AI
FHTX Stock Price, Quote & Chart | FOGHORN THERAPEUTICS INC (NASDAQ:FHTX) - ChartMill
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Strength Observed in Dianthus Therapeutics, Inc. (DNTH): Will Its 5.6% Increase Lead to Further Gains? - Bitget
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo! Finance Canada
FHTX Should I Buy - Intellectia AI
Aug Final Week: Can Foghorn Therapeutics Inc weather a recessionCPI Data & High Conviction Investment Ideas - baoquankhu1.vn
Setup Watch: Is Foghorn Therapeutics Inc part of any major index2026 Price Action Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Fundamentals Check: Is Foghorn Therapeutics Inc stock a good dividend stock2026 Earnings Impact & Daily Profit Focused Stock Screening - baoquankhu1.vn
Ideas Watch: Is Foghorn Therapeutics Inc stock a hidden gem2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
0.83%
2.04%
자본화:
|
볼륨(24시간):